ProCE Banner Activity

Global Perspectives on Biomarker-Driven Therapeutic Strategies in Pancreatic Cancer

Multimedia
Watch this on-demand Webcast of a live CCO Webinar in which global experts provide their recommendations on how biomarkers should inform the treatment of pancreatic cancer.

Released: March 15, 2021

Expiration: March 14, 2022

Share

Faculty

Dirk Arnold

Dirk Arnold, MD, PhD

Director
Asklepios Tumorzentrum Hamburg
Department of Oncology
AK Altona
Hamburg, Germany

Philip Agop Philip

Philip Agop Philip, MD, PhD, FRCP

Professor
School of Medicine
Wayne State University
Leader, Gastrointestinal Multidisciplinary Team
Department of Oncology
Karmanos Cancer Institute
Detroit, Michigan

Supporters

Supported by an educational grant from

AstraZeneca

Learning Objectives

  • Assess BRCA1/2 and other alterations leading to homologous repair deficiency in patients with advanced pancreatic ductal adenocarcinoma
  • Apply current data and expert recommendations to optimally use platinum-based chemotherapy in patients newly diagnosed unresectable pancreatic ductal adenocarcinoma and germline BRCA mutations
  • Plan therapeutic strategies for patients with advanced pancreatic ductal adenocarcinoma harboring BRCA1/2 or other DNA damage response mutations
  • Evaluate available data and ongoing clinical trials on emerging and investigational therapies for pancreatic ductal adenocarcinoma
  • Incorporate strategies to effectively identify and manage disease-related and treatment-related adverse events to support quality of life and continuation of therapy

Program Director Disclosure

Program Director

Dirk Arnold, MD, PhD

Director
Asklepios Tumorzentrum Hamburg
Department of Oncology
AK Altona
Hamburg, Germany

Dirk Arnold, MD, PhD, has disclosed that he has received consulting fees from Amgen, AstraZeneca, Bristol-Myers Squibb, Lilly, MSD, Pierre Fabre, and Roche; funds for research support from AstraZeneca, Bristol-Myers Squibb, and Pierre Fabre; fees for non-CME/CE services from Amgen, AstraZeneca, Bristol-Myers Squibb, MSD, Pierre Fabre, and Roche; and other financial or material support from AstraZeneca.

Faculty Disclosure

Primary Author

Philip Agop Philip, MD, PhD, FRCP

Professor
School of Medicine
Wayne State University
Leader, Gastrointestinal Multidisciplinary Team
Department of Oncology
Karmanos Cancer Institute
Detroit, Michigan

Philip Philip, MD, PhD, FRCP, has disclosed that he has received consulting fees from Ipsen, QED, and TriSalus; funds for research from AstraZeneca, Bayer, Incyte, Novartis, QED, and Rafael; and fees for non-CME/CE services from Bayer, Incyte, and Novartis.

Staff Disclosure

Staff

Petra Cravens, PhD

Editorial Contributor

Petra Cravens, PhD, has no relevant conflicts of interest to report.

Katie Eustace, MBA

Senior Director, Global Medical Education, Europe

Katie Eustace, MBA, has no relevant conflicts of interest to report.

Kevin Obholz, PhD

Editorial Director, Hematology/Oncology

Kevin L. Obholz, PhD, has no relevant conflicts of interest to report.

Timothy A. Quill, PhD

Senior Managing Editor

Timothy A. Quill, PhD, has no relevant conflicts of interest to report.

Justine Stanley, MSc

Editorial Contributor

Justine Stanley, MSc, has no relevant conflicts of interest to report.